Whole-Body Distribution of Donepezil as an Acetylcholinesterase Inhibitor after Oral Administration in Normal Human Subjects: A 11C-donepezil PET Study

سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 225

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_JNMB-5-1_001

تاریخ نمایه سازی: 12 تیر 1398

چکیده مقاله:

Objective(s): It is difficult to investigate the whole-body distribution of an orally administered drug by means of positron emission tomography (PET), owing to the short physical half-life of radionuclides, especially when 11C-labeled compounds are tested. Therefore, we aimed to examine the whole-body distribution of donepezil (DNP) as an acetylcholinesterase inhibitor by means of 11C-DNP PET imaging, combined with the oral administration of pharmacological doses of DNP.Methods: We studied 14 healthy volunteers, divided into group A (n=4) and group B (n=10). At first, we studied four females (mean age: 57.3±4.5 y), three of whom underwent 11C-DNP PET scan at 2.5 h after the oral administration of 1 mg and 30 μg of DNP, respectively, while one patient was scanned following the oral administration of 30 μg of DNP (group A). Then, we studied five females and five males (48.3±6.1 y), who underwent 11C-DNP PET scan, without the oral administration of DNP (group B). Plasma DNP concentration upon scanning was measured by tandem mass spectrometry. Arterialized venous blood samples were collected periodically to measure plasma radioactivity and metabolites. In group A, 11C-DNP PET scan of the brain and whole body continued for 60 and 20 min, respectively. Subjects in group B underwent sequential whole-body scan for 60 min. The regional uptake of 11C-DNP was analyzed by measuring the standard uptake value (SUV) through setting regions of interest on major organs with reference CT.Results: In group A, plasma DNP concentration was significantly correlated with the orally administered dose of DNP. The mean plasma concentration was 2.00 nM (n=3) after 1 mg oral administration and 0.06 nM (n=4) after 30 μg oral administration. No significant difference in plasma radioactivity or fraction of metabolites was found between groups A and B. High 11C-DNP accumulation was found in the liver, stomach, pancreas, brain, salivary glands, bone marrow, and myocardium in groups A and B, in this order. No significant difference in SUV value was found among 11C-DNP PET studies after the oral administration of 1 mg of DNP, 30 μg of DNP, or no DNP.Conclusion: The present study demonstrated that the whole-body distribution of DNP after the oral administration of pharmacological doses could be evaluated by 11C-DNP PET studies, combined with the oral administration of DNP.

کلیدواژه ها:

نویسندگان

Ikuko Mochida

Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine Osaka University Graduate School of Medicine Immunology Frontier Research Center

Eku Shimosegawa

Department of Molcular Imaging in Medicine, Osaka University Graduate School of Medicine Department of Molcular Imaging in Medicine, Osaka University Graduate School of Medicine

Yasukazu Kanai

Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine Department of Molcular Imaging in Medicine, Osaka University Graduate School of Medicine

Sadahiro Naka

Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine Osaka University Hospital

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. ...
  • Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, ...
  • Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, ...
  • Okamura N, Funaki Y, Tashiro M, Kato M, Ishikawa Y,Maruyama ...
  • Hiraoka K, Okamura N, Funaki Y, Watanuki S, Tashiro M, ...
  • Gjerloff T, Jakobsen S, Nahimi A, Munk OL, Bender D, ...
  • Gjerloff T, Fedorova T, Knudsen K, Munk OL, Nahimi A, ...
  • Funaki Y, Kato M, Iwata R, Sakurai E, Tashiro M, ...
  • Matsumoto K, Kitamura K, Mizuta T, Tanaka K, Yamamoto S, ...
  • Tanaka E, Kudo H. Subset-dependent relaxation in block-iterative algorithms for ...
  • Ravic M, Warrington S, Boyce M, Dunn K, Johnston A. ...
  • Clin Pharmacol. 2004;58(Suppl 1):34–40. ...
  • Watabe T, Naka S, Ikeda H, Horitsugi G, Kanai Y, ...
  • C-Dopenezil PET study in the normal rat. PLoS One. 2014; ...
  • EU/EMEA/CPMP: Position Paper on non-clinical safety studies to support clinical ...
  • US FDA: Guidance for Industry, Investigatorsand Reviewers, Exploratory IND Studies, ...
  • Logan J. Graphical analysis of PET data applied to reversible ...
  • نمایش کامل مراجع